ACTA Virtual Clinics on Adaptive Platform Trials 2024

ACTA will be holding a series of virtual clinics on Adaptive Platform Trials this year (subject to demand). For those who are keen to present their work, this will be a 15 min virtual presentation + 15 min panel discussion targeted at groups who are considering or planning an adaptive platform trial (early stages preferable).

If you are keen to present, please submit 3-4 lines on your trial to acta@acta.au.

We welcome those interested to learn more in this space and would like to attend these presentations. 

Below is the registration link for those who are keen to attend and/or present.

Confirmed dates and times for next session:

23 May 2024 (Thursday), 12-1pm (AEST)

Dr Xiaoying Chen

ACT-GLOBAL Adaptive Platform Trial for Stroke

Stroke is the second most common cause of death around the world. It’s also a major reason people lose their ability to live a normal life, especially in developing countries. The number of new stroke cases, deaths due to stroke, and people living with stroke increased significantly from 1990 to 2019.

There has been some progress in finding ways to manage stroke in patients who have had a stroke or are at high risk. But only a few immediate treatments have been shown to help: thrombolysis, endovascular thrombectomy, hemicraniectomy, stroke unit care, and aspirin. There’s still a need for more treatments that can improve results and can be used widely for stroke.

Randomised controlled trials (RCTs) are the best way to find out if treatments work. But traditional RCTs are often expensive, need a lot of resources, and take a lot of time because they only test one treatment at a time with fixed assumptions. On the other hand, platform trials can test many treatments at the same time and can add or remove treatments during the trial, which is more efficient. In the ongoing search for the best treatment methods for stroke patients, platform trials are seen as a promising new approach in stroke research. They have the potential to change the way stroke clinical research is done, leading to quicker and more effective treatments for this life-threatening disease.

As an adaptive platform trial, the main goal of ACT-GLOBAL is to find the treatment or treatments that are most likely to help stroke patients get better.

Speaker Bio:

Dr Chen has 20 years’ experience in multicenter clinical trials and 15 years spent designing and conducting large international stroke trials. She has been pivotal to the success of multiple world-class large international clinical trials, including as one of the Lead PIs of A multi-faCtorial, mulTi-arm, multi-staGe, randomised, gLOBal Adaptive pLatform trial for stroke (ACT-GLOBAL) aiming to be executed through 300+ hospitals in 20+ countries, Global Project Lead of landmark trial - The third, INTEnsive care bundle with blood pressure Reduction in Acute Cerebral haemorrhage Trial (INTERACT3) with 7000+ stroke patients enrolled from 120+ centres from 10 countries, Senior Project Lead of INTEnsive blood pressure Reduction in hyperacute Cerebral haemorrhage Trial (INTERACT4) with 2200+ stroke patients enrolled from 50+ centres in China, Senior Project Lead of Second Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED2) with 800+ stroke patients enrolled from 50+ centres in China, Global Project Lead of other large international clinical trials, including ENCHANTED, INTERACT2 and SAVE.  

For more information, please contact us at acta@acta.au